Huntsman (HUN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
Annual Meeting scheduled for April 29, 2026, with a definitive proxy statement filed on March 16, 2026.
Board unanimously recommends voting for all director nominees, emphasizing the value and contributions of each.
Voting matters and shareholder proposals
Shareholders are asked to vote on the re-election of all directors, with specific attention to José Antonio Muñoz Barcelo.
ISS and Glass Lewis recommend voting against Mr. Muñoz due to attendance below 75% in 2025.
Board strongly disagrees with proxy advisors and urges support for Mr. Muñoz, citing extenuating circumstances for absences.
Board of directors and corporate governance
Mr. Muñoz serves on the Compensation and Sustainability Committees and has been an independent director since 2022.
His attendance from 2022-2024 exceeded 93%, with 100% in 2024; in 2025, he attended 69% due to two high-profile business conflicts.
Absences were due to urgent meetings with global leaders on trade and tariffs, directly relevant to company interests.
Mr. Muñoz remains actively engaged through informal meetings and ad hoc input, beyond formal attendance.
Board values his unique industry experience and global perspective, considering his contributions vital.
Latest events from Huntsman
- Q2 2026 revenue up 14%, EBITDA up 62%, and Olin merger targets $300–400M in synergies.HUN
Q2 2026 - Olin and Huntsman shareholders to vote on a merger of equals, forming OlinHuntsman Corporation.HUN
Proxy filing - $12B+ merger forms a chemicals leader with $400M+ synergies and balanced governance.HUN
Investor presentation - $12B+ all-stock merger creates a chemicals leader with $400M+ synergies, closing H1 2027.HUN
M&A announcement - Board elections, compensation, and auditor ratified; independent chair proposal rejected.HUN
AGM 2026 - Net loss widened to $53M on flat revenue, with Advanced Materials outperforming other segments.HUN
Q1 2026 - Revenue fell 5%, net loss narrowed, and a 65% dividend cut preserved cash amid restructuring.HUN
Q3 2025 - Q2 2024 saw lower revenue and EBITDA, higher net income, and 9% sales volume growth.HUN
Q2 2024 - Q4 2024 saw revenue growth and improved EBITDA, but net loss and restructuring persist.HUN
Q4 2024